Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pembrolizumab (MK-3475) in Combination With Standard Therapy for Newly Diagnosed Glioblastoma

NCT03197506 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03197506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03197506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pembrolizumab (MK-3475) in Combination With Standard Therapy for Newly Diagnosed Glioblastoma
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 15, 2018
Completion date
June 6, 2028
Enrollment
52 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, gliosarcoma, supratentorial glioblastoma